Key result
Mutant Myo1b with truncated or replaced loop 4 resisted tropomyosin-induced inhibition of actin-activated ATPase activity and motility in vitro, but remained excluded from these filaments in cells.
Loop 4 of Myo1b modulates its interaction with actin-tropomyosin in vitro, but additional cellular factors determine the targeting of myosins I to specific actin filament subpopulations in vivo.
Does not alter clinical practice; leaves open how cellular factors govern myosin I targeting beyond loop 4 in vivo.
Structural studies of the class I myosin, MyoE, led to the predictions that loop 4, a surface loop near the actin-binding region that is longer in class I myosins than in other myosin subclasses, might limit binding of myosins I to actin when actin-binding proteins, like tropomyosin, are present, and might account for the exclusion of myosin I from stress fibers. To test these hypotheses, mutant molecules of the related mammalian class I myosin, Myo1b, in which loop 4 was truncated (from an amino acid sequence of RMNGLDES to NGLD) or replaced with the shorter and distinct loop 4 found in Dictyostelium myosin II (GAGEGA), were expressed in vitro and their interaction with actin and with actin-tropomyosin was tested. Saturating amounts of expressed fibroblast tropomyosin-2 resulted in a decrease in the maximum actin-activated Mg2+-ATPase activity of wild-type Myo1b but had little or no effect on the actin-activated Mg2+-ATPase activity of the two mutants. In motility assays, few actin filaments bound tightly to Myo1b-WT-coated cover slips when tropomyosin-2 was present, whereas actin filaments both bound and were translocated by Myo1b-NGLD or Myo1b-GAGEGA in both the presence and absence of tropomyosin-2. When expressed in mammalian cells, like the wild type, the mutant myosins were largely excluded from tropomyosin-containing actin filaments, indicating that in the cell additional factors besides loop 4 determine targeting of myosins I to specific subpopulations of actin filaments.
No takes yet. Share an insight, caveat, or question.
Lieto-Trivedi et al. (2007) studied this question. Mutant Myo1b (loop 4 truncated or replaced) vs. Wild-type Myo1b was evaluated on Actin-activated Mg2+-ATPase activity and motility in the presence of tropomyosin-2. Mutant Myo1b with truncated or replaced loop 4 resisted tropomyosin-induced inhibition of actin-activated ATPase activity and motility in vitro, but remained excluded from these filaments in cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: